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CRYSTAL ENGINEERING OF FLAVONOIDS  
 
 
PADMINI KAVURU 
 
ABSTRACT 
 
Crystal engineering is attracting attention in the pharmaceutical industry because the 
design of new crystal form of drugs can improve their stability, bioavailability and other 
relevant physical characteristic properties. Therefore, crystal engineering of 
nutraceuticals such as flavonoids by exploring their hydrogen bonding interactions can 
generate novel compounds such as pharmaceutical cocrystals. Flavonoids are 
polyphenolic secondary plant metabolites that are present in varying levels in fruits, 
vegetables and beverages. The “French paradox”, low cardiovascular mortality rate in 
spite of high intake of saturated fat among the Mediterranean populations made 
flavonoids an appropriate target for therapeutic researchers.  
                    The work herein deals with the crystal engineering of two flavonoids, 
quercetin and hesperetin, which are already known to exhibit antioxidant properties and 
reduce cardiovascular effects in humans. However, they have limited bioavailability and 
poor water solubility. Several new forms of quercetin and hesperetin in the form of 
solvates and cocrystals were synthesized. These new crystal forms were characterized by 
various techniques: FT-IR, DSC (Differential Scanning Calorimetry), single X-ray 
diffraction, powder X-ray diffraction, TGA (Thermal Gravimetric Analysis) and 
 x  
melting point. The new compounds were also studied via dissolution studies performed in 
1:1 ethanol/water (V/V%). Thus, crystal engineering proves to be effective way to 
enhance the solubility and bioavailability of the target flavonoid molecules. 
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1. INTRODUCTION 
 
1.1 Nutraceuticals 
 
 
The term ‘Nutraceutical’ is an intermediate of nutrition and pharmaceutical.1 It is used to 
describe a medicinal or nutritional component of food, plant or naturally occurring 
material in purified or concentrated form claimed to have a medicinal effect on human 
health. Such foods are also called functional foods. It can also refer to individual 
chemical present in common foods. The position of nutraceuticals on the legislative 
grounds is marginal between pharmaceutics and food.  
                  The term nutraceutical was coined by Dr. Stephen De Felice (founder and 
chairman of Foundation of Innovation in Medicine) in 1976.1 He defined it as:  
“Nutraceuticals are ‘food, or parts of food, that provide medical or health benefits, 
including the prevention and treatment of disease”. Nutraceuticals include a wide range 
of products, such as polyphenols (Flavonoids), vitamins, oils from fish and flax seed, 
glucosamine, chondroitin, resveratrol, calcium-fortified juices etc.1
 
1.2 Flavonoids         
     
Flavonoids are naturally occurring polyphenolic compounds that are found in fruit, 
vegetables, grains, bark, roots, stems, flowers, tea, and wine.2 These natural products 
were known for their beneficial effects on health long before flavonoids were isolated as 
 2  
the effective compounds. There are more than 4000 varieties of flavonoids which have 
been identified till now and are considered responsible for the attractive colors of flowers, 
fruit, and leaves.3, 4 These are responsible for many of the plant colors that dazzle us with 
their brilliant shades of yellow, red and orange. Many of the flavonoids are dietary 
antioxidants and constituents of medicinal herbs. These compounds were discovered in 
by a Hungarian scientist, Dr. Albert Szent-Gyorgyi in 1938, who discovered Vitamin C 
(Nobel laureate) by mistake. Rusznyák and Szent-Györgi (1936) suggested that 
flavonoids be known as vitamin P or vitamin C2.5-8 However, by the 1950’s the vitamin 
claim had been abandoned due to a lack of substantive evidence. 
                  Flavonoids are also known as plant secondary metabolites which does not 
effect the normal growth, development or reproduction of organisms like the primary 
metabolites neither their absence result in immediate death.9 But, these compounds are 
used as defenses against predators, parasites and diseases, for interspecies competition, 
and to facilitate the reproductive processes (coloring agents, attractive smells, etc) and 
hence they are called as the “First Line of Defense”.10 The research on flavonoids took a 
rapid momentum with the discovery of the French paradox, i.e., low cardiovascular 
mortality rate observed in Mediterranean populations with red wine consumption and a 
high saturated fat intake.22, 23 The flavonoids in red wine are responsible for this effect. In 
addition, epidemiologic studies suggest a protective role of dietary flavonoids against 
coronary heart disease. After a number of subsequent studies on animals it was found that 
flavonoid intake is inversely correlated with mortality due to coronary heart disease.11, 12  
These potential benefits are being used to promote the consumption of flavonoid-rich 
foods, beverages and dietary supplements. 
1.3 Structure and classification 
 
The basic structure of flavonoids is based on the 15 carbon skeleton, i.e. C6 – C3 – C6.The 
two ‘C6’ represents the number of carbon atoms of the two phenyl groups and the C3 
represents the number of carbon atoms that bridge the two phenyl rings by a linear three 
carbon chain.7-10 Figure 1.1 explains the above description in most convenient way.  
                                      
                                           
 
Figure 1.1 Skeleton of Flavonoid 
 
In some of the flavonoids, the three carbon linear chain is replaced by a chromane ring 
and the position of ring could be at 2, 3 or at 4th carbon atom. The overall structure now 
consists of three rings A, B and C. The position of the ring B varies from one class of 
flavonoid to the other. 
                                             
Figure 1. 2 Structure of Flavonoid with the chromane ring 
 
In some of the flavonoids, the six-membered heterocyclic ring C occurs in an isomeric 
open form or is replaced by a five - membered ring.  The oxygen bridge involving the 
central carbon atom (C2) of the three carbon chain occurs in a limited number of cases 
resulting in a heterocyclic ring which is of the furan type. 
 3  
                                              
 
 
Figure 1.3 Aurones (2-benzyl-coumarone) 
 
Most of the flavonoids occur as glucosides in which the C6-C3-C6 aglycone part of the 
molecule is linked with different number of sugars. If the linkage of the sugar to the 
flavonoid aglycone is through an OH group then these are called as O-glycosylflavonoids 
and if the linkage is through C-C bond then these are called as C-glycosylflavonoids.17  
The type of sugar and the position of sugars vary for different glycosides. These have a 
more complex structure than the phenolic skeleton materials.  
Glycoside = Aglycone + Glycone (sugar) 
 
Figure 1.4 Example of Glycoside, Rutin (quercetin-3-rutinoside) 
The most common citrus flavanone-glycosides are rutin, natrirutin, naringin, hesperedin 
and neohesperidin. Naringin (in grapefruits) and hesperidin (in oranges) are the two 
major flavonoid-glycosides present in the citrus fruits, and are primarily concentrated in 
the peel and the tissue of the fruit.18 The table below represents the structures of various 
flavonoids. 
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Table 1.1 Structures of different of Flavonoids 
 
 
Anthocyanidins 
       
 
   Flavanols 
    
    
 
Flavonols 
      
 
 
     Flavonones 
          
 
 
 
Flavones 
            
 
      
  Isoflavones 
        
 
Flavonoids are divided into various classes on the basis of their molecular structure.19 The six 
main groups of flavonoids are listed in Table 1.2, which includes the known members of 
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each group and the food sources in which they are present.  
Table 1.2 Classification Flavonoids and their common food source 
 
Flavonoid 
Subclass 
Dietary Flavonoids Some Common Food 
Sources 
Anthocyanid
ins 
Cyanidin, Delphinidin, 
Malvidin, Pelargonidin, 
Peonidin, Petunidin 
Red, blue and purple berries, red 
and purple grapes, red wine 
Flavanols Monomers (Catechins): 
Catechin, Epicatechin, 
Epigallocatechin 
Epicatechin gallate, 
Epigallocatechin gallate 
Dimers and Polymers: 
Theaflavins, Thearubigins, 
Proanthocyanidins 
Catechins: Teas (particularly 
green and white), chocolate, 
grapes, berries, apples 
Theaflavins, Thearubigins: Teas 
(particularly black and oolong) 
Proanthocyanidins: Chocolate, 
apples, berries, red grapes, red 
wine 
Flavonones Hesperetin, Naringenin, 
Eriodictyol 
Citrus fruits and juices, e.g., 
oranges, grapefruits, lemons 
Flavonols Quercetin, Kaempferol, 
Myricetin, Isorhamnetin 
Widely distributed: yellow 
onions, scallions, kale, broccoli, 
apples, berries, teas. 
Flavones Apigenin, Luteolin Parsley, thyme, celery, hot 
peppers, 
Isoflavones Daidzein, Genistein, Glycitein Soybeans, soy foods, legumes 
 
1.4 Bioactivity and bioavailability  
 
Flavonoids are widely known for their antioxidant activity. Important effect of flavonoids is 
the scavenging of oxygen-derived free radicals. In vitro experimental systems showed that 
flavonoids possess anti-inflammatory, anti-allergic, antiviral, and anti-carcinogenic 
properties.20 An overview of the hypothetical links between the working mechanisms and 
clinical effects of flavonoids is given in Figure 1.5.21  
 Figure 1.5 Hypothesis of the links between the working mechanisms of flavonoids and their effects on 
disease. NO, nitrous oxide 
 
        
One clue to the health benefits of flavonoids comes from studies of the "French paradox”.22 
French eat almost four times more butter and three times more lard-and have higher 
cholesterol levels and blood pressures-than do Americans and yet the French are 2.5 times 
less likely than Americans to die of coronary heart disease. Many people have suggested that 
the liberal French consumption of red wine protects against coronary heart disease, 
apparently by lowering cholesterol levels or preventing abnormal blood clots. In fact, at least 
eight medical studies have found that a glass or two of wine daily protects against heart 
disease. But some studies have reported that red wine is better than white wine, suggesting 
that some of the benefits might be unrelated to the alcohol. The antioxidant property of 
flavonoids can be explained in the following way: Flavonoids are oxidized by radicals, 
resulting in a more stable, less-reactive radical. In other words, flavonoids stabilize the 
reactive oxygen species by reacting with the reactive compound of the radical. Because of 
 7  
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the high reactivity of the hydroxyl group of the flavonoids, radicals are made inactive, 
according to the following equation: 22
                             Flavonoid (OH) + R• ? Flavonoid (O•) + RH (1)                         where, R• 
is a free radical and O• is an oxygen free radical. Selected flavonoids can directly scavenge 
super oxides; whereas other flavonoids can scavenge the highly reactive oxygen derived 
radical called peroxynitrite. Epicatechin and rutin are also powerful radical scavengers. The 
scavenging ability of rutin may be due to its inhibitory activity on the enzyme xanthine 
oxidase. By scavenging radicals, flavonoids can inhibit LDL oxidation in vitro.24 This action 
protects the LDL particles and, theoretically, flavonoids may have preventive action against 
atherosclerosis.  
                 With the exception of flavanols (catechins and proanthocyanidins), flavonoids 
occur in plants and most foods as glycosides. Even after cooking, most flavonoid glycosides 
reach the small intestine intact. Only flavonoid aglycones and flavonoid glucosides (bound to 
glucose) are absorbed in the small intestine, where they are rapidly metabolized to form 
methylated, glucuronidated or sulfated metabolites.25 Hollman and Katan suggested that the 
glycosylated forms of quercetin are absorbed more readily than are the aglycone forms; 
however, this has been questioned by other researchers. The role of flavonoid glycosylation 
in facilitating absorption is questioned by the fact that catechin, which is not glycosylated in 
nature, is absorbed relatively efficiently.  As most of the flavonoids are poorly absorbed by 
the body and the major percentage is excreted out which, limits its bioavailability. Even 
though numerous strategies exist for enhancing the bioavailability of drugs with low aqueous 
solubility, the success of these approaches is not yet able to be guaranteed and is greatly 
dependent on the physical and chemical nature of the molecules being developed. Crystal 
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engineering offers a means to improved solubility and dissolution rate and stability, which 
can be adopted through an in-depth knowledge of crystallization processes and the molecular 
properties of active pharmaceutical ingredients.26  
1.5 Crystal Engineering 
 
Crystal engineering is described as the ‘exploitation of noncovalent interactions between 
molecular or ionic components for the rational design of solid-state structures that might 
exhibit interesting electrical, magnetic, and optical properties’. It is also recognized that it ‘is 
becoming increasingly evident that the specificity, directionality, and predictability of 
intermolecular hydrogen bonds can be utilized to assemble supramolecular structures of, at 
the very least, controlled dimensionality’.27 The noncovalent interactions which have been 
exploited in this field are hydrogen bonding, π…π, dipole interactions, ionic bonds, 
hydrophobic interactions, London dispersion forces etc. The term crystal engineering was 
coined by Pepinsky in 1955, but it was popularized by the work of Schmidt in solid state 
photo chemistry and this is considered as the beginning era of crystal engineering.28 By his 
work it was clear that the chemical and physical properties of the crystalline solids are 
dependent on the arrangement of the molecules in the crystal lattice.  
                 Gautam Desiraju, in this context define crystal engineering as below: “Crystal 
engineering is the understanding of intermolecular interactions in the context of crystal 
packing and in the utilization of such understanding in the design of new solids with desired 
physical and chemical properties”.  
Crystal engineering can be used to manipulate the solubility and dissolution rate of the active 
pharmaceutical ingredients (API) in the crystalline state without compromising with its 
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bioactivity. There are many possible ways that may be achieved from recent developments in 
the study of molecular solids and reviews topical issues such as habit modification, 
polymorphism, solvation, co-crystal formation and surface modification. Therefore, 
particular attention is paid to the area of co-crystallization, which is an emerging area of 
strategic importance to the pharmaceutical sector.27  
                                                        
1.5.1 Supramolecular Chemistry 
 
Supramolecular chemistry is a relatively new field of chemistry which focuses literally on 
going "beyond" molecular chemistry.29 The importance of supramolecular chemistry was 
recognized by Donald J. Cram, Jean-Marie Lehn, and Charles J. Pedersen and for their work 
in this area they were awarded Nobel Prize for Chemistry in 1987. The important 
breakthrough that allowed the elucidation of the double helical structure of DNA occurred 
when it was realized that there were two separate strands of nucleotides connected through 
hydrogen bonds. The utilization of noncovalent bonds is essential to replicate because they 
allow the strands to be separated and used to template new double stranded DNA. The 
development of selective "host-guest" complexes, in which a host molecule recognizes and 
selectively binds a certain guest, was cited as an important contribution. Unlike, the organic 
synthesis  that involves the making and breaking of covalent bonds to synthesize a desired 
molecule, supramolecular chemistry utilizes far weaker and reversible noncovalent 
interactions, such as hydrogen bonding, metal coordination, hydrophobic forces, van der 
Waals forces, pi-pi interactions, sometimes electrostatic effects to assemble molecules into 
multimolecular complexes. Various fields that are classified under supramolecular chemistry 
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include molecular self-assembly, molecular recognition, host-guest chemistry, mechanically-
interlocked molecular architectures, and dynamic covalent chemistry.30 It is important for the 
development of new pharmaceutical therapies by understanding the interactions at a drug 
binding site. In addition, supramolecular systems have been designed to disrupt protein-
protein interactions that are important to cellular function. It also has application in green 
chemistry where reactions have been developed where the reactions take place in the solid 
state directed by non-covalent bonding. Such procedures are highly desirable since they 
reduce the need for solvents during the production of chemicals.  
1.5.2 Supramolecular synthons 
 
Supramolecular synthons are the smallest structural units within which is encoded all the 
information inherent in the mutual recognition of molecules to yield solid state 
supermolecules, that is, crystals. A key aspect of crystal engineering is therefore the 
dissection of a target network into supramolecular synthons not the molecular synthons 
which connect the supramolecular synthons.31 Such a dissection simplifies the analysis of a 
target network and is important in crystal engineering because it recognizes the 
interchangeability of supramolecular synthons in a family of structures.32, 33 Supramolecular 
synthons are classified into two categories: supramolecular homosynthons and 
supramolecular heterosynthons.34 The supramolecular homosynthons are formed between 
the same, self-complementary functional groups and supramolecular heterosynthons are 
formed between different but complementary functional groups. Examples of supramolecular 
homosynthons include the dimers formed between carboxylic acids 35, 36 and amides 37 
whereas supramolecular heterosynthons include carboxylic acid···amide, 38-42 
hydroxyl···pyridine, 43-45 and carboxylic acid···pyridine.46-49
         
(a) (b) 
 
Figure 1.6 Supramolecular synthons: (a) Carboxylic acid homosynthon, 
(b) Carboxylic acid•••pyridine heterosynthon 
 
 
The supramolecular homosynthons usually exists in structures of single-component 
compounds, for example the carboxylic acids exists as dimers. Where as, if multiple 
functional groups are present, a supramolecular heterosynthon is more likely to be formed as 
the formation of heterosynthons wins over the homosynthons when ever these two are 
competing with each other. When a supramolecular heterosynthon is formed between two 
functional groups that are located on different molecules, a multicomponent is formed.  
1.5.3 Cocrystals 
 
Cocrystals belong to the class of compounds which are long known but little studied. Earlier, 
cocrystals were known with different names like; molecular compounds,50 organic molecular 
compounds,51 addition compounds,52 molecular complexes,53 solid-state complexes,54 or 
heteromolecular crystals.55  In1844, the first cocrystal of benzoquinone and hydroquinone 
was synthesized by Wohler, and then followed by studies of halogen derivatives of 
quinhydrone.50, 56 Until 1960 the structural information for the cocrystal was absent. The 
elucidation of DNA structure 57, 58  through X-ray analysis inspired many people to come out 
with numerous nucleobase complexes in 1950’s and 60’s 59-62 and then the term “cocrystal” 
 12  
was first coined in this context 63 later it was subsequently popularized by Etter.64 During this 
time, Hoogstein came up with the new base pair called “Hoogstein base pair”, a cocrystal 
formed between 9-methyladenine and 1-methylthymine.61                                          
 
 
Figure 1.7 Crystal structure of the triclinic form of quinhydrone 
                                       
 
Figure 1.8 The Hoogsteen base-pair 
 
The term cocrystal sounds very simple but the definition is often a topic of debate.65, 66 The 
Zaworotko research group defines cocrystal as: “A cocrystal is a multiple component crystal 
in which all components (molecule or ion and a molecular cocrystal former) are solid under 
ambient conditions when in their pure form”. All components are solid under ambient 
conditions has important practical considerations, because synthesis of cocrystals can be 
achieved via the solid-state.67 Aakero¨y and co-workers,68 they defined cocrystals as (i) 
compounds constructed from neutral molecules; (ii) made from reactants that are solids at 
ambient conditions; and (iii) structurally homogeneous crystalline materials that contains at 
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least two neutral building blocks with a well-defined stoichiometry. A broad definition of a 
cocrystal given by Dunitz: “a crystal containing two or more components together”69 would 
include molecular adducts, salts, solvates/hydrates, inclusion compounds, etc. What ever way 
people define the term cocrystal, the field of cocrystal is attaining the heights of excellence, 
and Figure 1.9 reveals the growing interest in the subject. Therefore, it is evident that 
cocrystals play a vital role in pharmaceutical science and elsewhere. 
 
 14  
 
 
 
 
 
 
 
 
 
 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
0
50
100
150
200
250
300
N
um
be
r o
f h
its
 c
on
ta
in
in
g 
th
e 
te
rm
 "C
oc
ry
st
al
"
Year
 
Figure 1.9 Occurrence of the term “cocrystal” in papers published between 1991 and 2007 
 (SciFinder search 2/2008). 
 
1.5.4 Pharmaceutical cocrystals 
 
Most of the active pharmaceutical ingredients (APIs) are administered in the solid state as 
part of an approved dosage type like tablets, capsules, etc as it is the convenient and compact 
format to store a drug. 
               
  
 
Figure 1.10 Different forms of drugs in which they are administered. 
 
APIs can exist in a variety of distinct solid forms, where each form may display unique 
physicochemical properties such as hygroscopicity, morphology, and (most importantly) 
solubility. The solid form of the drug dictates the properties like stability, hygroscopicity, 
dissolution rate, solubility and bioavailability. Figure 1.10 represents the different ways in 
which drugs are administered.70 This makes the pharmaceutics to look for a crystal form with 
the best properties for therapeutic use and manufacturability. Therefore, whatever form of 
drug is selected, it must be amenable to handling and processing and as a drug, it must be 
effective and safe. Sometimes, the pharmaceutic developers come across a problem, that the 
most common polymorphic form of the drug is least stable. Therefore the current approaches 
to change the properties of APIs include the utilization of ionic salts, solvates, hydrates, and 
polymorphs.71 In this context pharmaceutical cocrystallization is potentially attractive for 
improving the material properties while leaving an API unaltered. The intellectual property 
implications of creating co-crystals are also highly relevant. A pharmaceutical co-crystal can 
described as “a multiple component crystal in which at 20 least one component is molecular 
and a solid at room temperature (the co-crystal former) and forms a supramolecular synthon 
with a molecular or ionic API”.72, 73 The first application of crystal engineering to generate of 
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pharmaceutical co-crystals was a series of studies by Whitesides et al. with the use of 
substituted barbituric acid, including barbital and melamine derivatives and generated a 
supramolecular ‘linear tape,’ ‘crinkled tape,’ and ‘rosette’ motifs.74-80
                                           
(a) (b) 
Figure 1.11 Crystal packing of 1:1 co-crystals of 5, 5-diethylbarbituric acid (barbital) 
 
To date, many pharmaceutical cocrystals have been reported in the scientific and patent 
literature and most of the cocrystals have been found to exhibit improved material properties 
like solubility, stability, bioavailability etc over the pure API. A few examples 
pharmaceutical cocrystals are: carbamazepine (CBZ), aspirin, profens, piracetam, 
caffeine, loracarbef, cephalexin, cefaclor, conazoles, topiramate, modafinil, phenytoin, 
olanzapine, nabumetone, fluoxetine, theophylline, sulfadimidine, trimethroprim, and 
paracetamol.81-97 
                                                                      
                          (a)                                                                          (b) 
Figure 1.12 (a) Itraconazole•succinic acid cocrystal, (b) Carbamazepine•saccharin cocrystal 
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Therefore, the applications of concepts of supramolecular synthesis and crystal engineering 
to the development of pharmaceutical cocrystals offer many opportunities for the drug 
development and delivery. So it would not be exaggeration in saying that sooner or later 
pharmaceutical cocrystals will gain a broader foothold in drug formulation. 
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2. CSD ANALYSIS 
 
2.1 Cambridge Structural Database 
 
The Cambridge Structural Database (CSD) is an important product of the Cambridge 
Crystallographic Data Centre (CCDC), which was established by Olga Kennard at 
Cambridge University in 1965.98 It comprises software for database access, structure 
visualization and data analysis, and structural knowledge. It has a collection of bibliographic, 
chemical and crystallographic information for organic molecules and metal-organic 
compounds whose 3D structures have been determined using X-ray diffraction or neutron 
diffraction and the information is stored in form of a cif file (.cif). The collection also 
includes the results of single crystal studies powder diffraction studies which yield 3D atomic 
coordinate data for at least all non-H atoms. The crystal structure data arising from 
publications in the open literature and private communications via direct data deposition are 
also assimilated in the CSD.  
                     The basic softwares that CSD relies on are: ConQuest (search and information 
retrieval), Mercury (structure visualization), Vista (numerical analysis) and PreQuest 
(database creation). The CSD helps to compare existing data with that obtained from crystals 
grown in their laboratories. It is evident from Figure 2.1 that there is a rapid growth of the 
CSD since 1970, and it is predicted growth would increase exponentially during the decade 
2001-2010. Thus CSD is proves to be an inexhaustible source for crystallographers and 
interpretation of existing crystal structures with complete knowledge on interplay between 
supramolecular synthons would help in designing new multicomponent crystals. 
                             
(a) (b) 
(b)  
Figure 2.1 (a) Growth of the CSD since 1972, (b) Predicted growth of the CSD during the decade 2001 - 
2010 
  
2.2 CSD statistics for Phenols and Polyphenols 
 
Flavonoids are known as polyphenolic compounds and to design new crystal forms (solvates, 
cocrystals etc) of these compounds it is necessary to know about the statistics of existing 
synthons of hydroxyl groups with other functional groups present in the CSD. Although 
phenols and alcohols have the hydroxyl group common in their structures as they differ in 
acidity. Phenols have relatively higher acidities due to the aromatic ring tightly coupling with 
the oxygen and a relatively loose bond between the oxygen and hydrogen. The acidity of the 
hydroxyl group in phenols is intermediate between that of aliphatic alcohols and carboxylic 
acids (their pKa is between 10 and 12). The polyphenols for the CSD search were recognized 
by the presence of more than one hydroxyl group per molecule as represented in the Figure 
2.2. 
 
                                          Figure 2.2 Structure of polyphenol for the CSD search 
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All the searches were done by considering the constraints: no ions, only organics, R factor: ≤ 
7.5% and structures with 3D coordinates. The statistics for the occurrence of various 
interactions of phenols and polyphenols with other functionalities in the CSD are tabulated 
below. 
Table 2.1 CSD statistics for Phenols and Polyphenols (January 2008 update) 
 
Moieties present 
in a structure 
No. Struc  
(Phenols) 
Structures 
with synthon 
No. Struc 
(Polyphenols)
Structures 
with synthon 
 
*OH 
(Phenols only) 
 
6932 
 
O-H…OH (synthon I) 
1320/ 6932 (19.0%) 
 
1196 / 6932 
(19.2%) 
 
O-H…OH 
492 / 1196 (41.1%) 
 
*OH & CO 
(ket & ald) 
 
960 
O-H…CO (synthon II) 
569 / 960 (67.0%) 
 
& O-H…OH (phenolic) 
202 homosynthons 
(20.0%) 
 
446 
O-H…CO 
186 / 446 (41.7%) 
 
& O-H…OH (phenolic)
163 homosynthons 
(36.6%) 
 
*OH & Narom
 
566 
O-H…Narom (synthon III)
315 / 566 (59.3%) 
 
& O-H…OH (phenolic) 
88 homosynthons 
(15.5%) 
 
151 
O-H…Narom
128 / 151 (84.8%) 
 
& O-H…OH (phenolic)
46 homosynthons 
(30.5%) 
 
*OH & O 
(ether) 
 
2391 
O-H…O (synthon IV) 
278 / 2391 (11.6%) 
 
& O-H…OH (phenolic) 
383 homosynthons 
(16.0%) 
 
330 
O-H…O 
66 / 330 (23.5%) 
 
& O-H…OH (phenolic)
131 homosynthons 
(39.7%) 
 
*OH & CONH2
(1o amides) 
 
85 
O-H…O=C (synthon V)
16 / 85 (%) 
 
OH…NH2 (synthon VI)
14 / 85, (16.5%) 
 
& O-H…OH (phenolic) 
6 homosynthons 
(7.1%) 
 
10 
O-H…O=C 
3 / 10 (30%) 
 
OH…NH2  
8 / 10 (80%) 
 
& O-H…OH (phenolic)
2 homosynthons 
(20%) 
   
Constrains: no ions, only organics, R factor: ≤ 7.5% and structures with 3D coordinates 
* represents phenolic –OH group 
 
2.3 Interactions of phenolic -OH group with other functional groups 
 
The CSD search reveals that there are 6232 hits for phenols and 1196 polyphenols 
(constraints: no ions, only organics, R factor: ≤ 7.5% and structures with 3D coordinates). 
HO O
H
 
Figure 2.3 Supramolecular phenolic OH OH homosynthon (Synthon I) 
 
 
Out of 6232 phenols the OH…OH phenolic supramolecular homosynthon was found in 
19.0% structures and out of 1196 polyphenols it was 41.1%. The bond range for synthon I 
was determined by the histogram generated by Vista software and it was found to be 2.5-3.07 
Å (cut off range). This implies that the remaining structures form supramolecular 
heterosynthons in the presence of other competing groups and the Figure 2.4 represents the 
cut off range for synthon I. 
 
 
Figure 2.4 Histogram for synthon I 
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The search for the entries with phenolic –OH group and the carbonyl group (aldehydes and 
ketones only) revealed that out of 960 hits 67.0% were found to have phenolic OH…CO 
supramolecular heterosynthon (synthon II) and only 20.0% have OH…OH phenolic 
supramolecular homosynthon (synthon I) 
O
H
O C
 
Figure 2.5 Supramolecular phenolic OH CO heterosynthon (Synthon II) 
 
 In case of polyphenols the presence of synthon II was only 41.7% and 36.6% have synthon I 
out of 446 entries with polyphenols and carbonyl compounds. The cut off range for synthon 
II was determined as 2.5-3.10 Å as shown in Figure 2.6. 
 
          
Figure 2.6 Histogram for synthon II 
 
Another search for the occurrence of phenolic OH…Narom supramolecular heterosynthon 
(synthon III) among the structures containing aromatic nitrogen with phenols and 
polyphenols was made. 
 
Figure 2.7 Supramolecular phenolic OH Narom heterosynthon (Synthon III) 
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The search results in 566 hits for compounds containing aromatic nitrogen and phenols. Out 
of the 566 hits 59.3% were found to have synthon III and 15.5% synthon I. For polyphenols 
the percentage for the occurrence of synthon III is much higher than that of phenols. Out of 
151 total structures containing polyphenols and aromatic nitrogen, 84.8% were found to have 
synthon III and 30.5% have synthon I. The distance range for synthon III was found to be 
2.5-3.125 Å as shown in Figure 2.8. 
 
 
Figure 2.8 Histogram for synthon III 
 
The search for the phenolic OH…O supramolecular heterosynthon (synthon IV) for ether with 
phenols and polyphenols shows that ethers are not good hydrogen bond acceptors as other 
functional groups. Even though the occurrence ethers with phenols and polyphenols is high 
when compared to other functional groups, out of 2391 hits only 11.6% of the total structures 
are capable of forming synthon IV and 16.0% form synthon I.  
O
H
O
 
Figure 2.9 Supramolecular phenolic OH O heterosynthon (Synthon IV) 
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For polyphenols out of 330 hits 23.5% were found to have the synthon IV and 39.7% form 
synthon I. The distance range for the occurrence of synthon IV was found to be 2.55-3.07 Å. 
 
 
Figure 2.10 Histogram for synthon IV 
 
 
The similar kind of search was made for the presence of amides with phenols and 
polyphenols was made for the occurrence of phenolic OH…CO (synthon V) and phenolic 
OH…NH (synthon VI) supramolecular heterosynthons. Out of 85 hits containing phenols and 
amides only 18.8% hits form the synthon V and 16.5% form synthon VI and only 7.1% of the 
total hits form synthon I.  
O H O
NH2                                         
O
H
O
NH
H  
                      
                               (a)                                                                     (b) 
 
Figure 2.11 (a) Supramolecular phenolic OH CO; (b) Supramolecular phenolic OH NH2 
heterosynthons synthon 
 
There were only 10 hits for amides and polyphenols and out of which only 3 hits were found 
to form synthon V and 8 hits form synthon VI and only 2 hits were found to form synthon I. 
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The bond ranges for the synthons V and VI were found to be 2.6-3.0 Å, 2.75-3.175 Å and 
respectively as shown in Figure 2.12. 
                
                                     (a)                                                                      (b) 
  
Figure 2.12 Histogram for (a) Synthon V; (b) Synthon VI 
 
2.4 Discussions 
Upon reviewing the statistics obtained from CSD searches, it is evident that aromatic 
nitrogen seems to be more prominent and competitive functional group to hydrogen bond 
with phenols and polyphenols. Even the carbonyls are good competitors for hydrogen 
bonding with the phenols and polyphenols. The data obtained from CSD statistics is useful in 
selecting the cocrystal formers (CCFs) that contains the competitive functional groups and 
are capable of forming hydrogen bond to the target nutraceuticals. Compounds containing 
aromatic nitrogen, carbonyl and amide functional groups are good candidates as CCFs for 
polyphenolic compounds such as flavonoids. Thus CSD proves to be very good tool for 
crystal engineering and would provide a valuable insight for crystal engineering strategies in 
generation of new multicomponent materials. 
 
 
 
 25  
 
 
3. QUERCETIN 
 
 
Quercetin (3, 3’4, 4’, 5-7-pentahydroxyflavone) is a bio flavonoid which is widely 
distributed in the plant kingdom.99-102 It is the most abundant of all the flavonoid 
molecules found in many often consumed foods including apples, citrus fruits, onions, 
tea, berries and vegetables, as well as many seeds, nuts, flowers, barks and leaves.103 It is 
also present in medicinal botanicals like Ginkgo biloba, Hypericum perforatum, 
Sambuscus Canadensis and many others.104   
 
Figure 3.1 Structure of Quercetin 
3.1 Description          
 
 Quercetin (Mol Wt = 302.2) is a bioflavonoid (pigment), found in almost all herbs, 
fruits, and vegetables. Bioflavonoids provide the body with anti-inflammatory and 
antioxidant protection, and quercetin is one of the most powerful and effective herbal 
anti-inflammatory, and antioxidant supplements in the market today.105, 106 Quercetin has 
been shown to prevent the development of a variety of conditions related to inflammation 
by direct inhibition of several initial processes of inflammation and free-radical damage, 
including arthritis, allergies, macular degeneration, heart disease and various forms of 
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cancer.107 Quercetin also shows anti-tumor properties.108 The estimated average daily 
dietary consumption of quercetin is about 30 mg/day. However, the manufacturer’s 
recommended daily dose of over-the-counter quercetin supplements ranges from 400– 
1200 mg/day.109 There is no recommended standard dose for quercetin but there have 
been some occasional reports of nausea when taken as high doses in supplements.106 
Quercetin exhibits poor solubility in water, it is practically insoluble in water but it is 
soluble in 100% sodium hydroxide and methanol, but in its glycoside form (with a sugar 
attached), which is the common form of its occurrence in fruits and vegetables, is more 
soluble in the body.110 Some of the glycoside forms of quercetin are rutin and quercitrin.  
3.2 Strategy for Crystal Engineering of Quercetin 
 
The quercetin molecule consists of three rings designated A, B and C respectively and is 
illustrated in Figure 3.2. The five hydroxyl groups, labeled as a-e can act as hydrogen 
bond acceptors and/or donors and the ether and carbonyl moieties are capable of serving 
as hydrogen bond acceptors.  
O
OHd
OHe
OHb
OHa
O
 B
CA
OHc
 
Figure 3.2 Representation of different rings in Quercetin 
 
 
Based on the CSD search as discussed in Chapter 2 for the occurrence of supramolecular 
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synthons between polyphenols and other functionalities, aromatic nitrogen, carbonyls and 
amides look more promising competitors for hydrogen bonding.   To date, the crystal 
structure of pure quercetin is not known but there are two entries for quercetin dihydrate 
with ref codes FEFBEX111 and FEFBEX01112 and a formamide solvate (EVIJUO) 113 and 
other hydrates (LORKEI) 114 in the CSD. Figure 3.3 represents the packing in the 
quercetin dihydrate.  The hydrogen bonding for the dihydrates of quercetin with the ref 
codes FEFBEX and FEFBEX01 are same but the R factor for FEFBEX01 (Rfac 4.8) is 
better than FEFBEX (Rfac 9.5). 
                    
                                                  
Figure 3.3 Hydrogen bonding in Quercetin dihydrate 
 
In the dihydrate form quercetin crystallizes with two water molecules that participate in 
extended hydrogen bonding network through the crystal lattice. In the crystal structure 
quercetin exists as a dimer which is formed by the OHb and the adjacent carbonyl moiety 
and these are also involved in the intramolecular hydrogen bonding in the dimer (circled 
in Fig 3.3). All the hydroxyl and carbonyl groups and the water molecules participate in 
hydrogen bonding. All the three rings of quercetin molecule in the crystal lattice are not  
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planar. The rings A and C lie in the same plane whereas the ring B is not. The dihedral 
angle between the plane containing rings A and C and the plane containing ring B is 
8.10o as shown in Figure 3.4. The overall hydrogen bonding leads to the stacking of 
infinite 2 D sheets.  
                                 
Figure 3.4 Illustration of dihedral angle between the planes. (Red plane contains rings A, C and the 
blue plane contains ring B) 
 
 
3.3 Solvates of Quercetin 
 
Three solvates of quercetin with pyridine, tetrahydrofuran (THF) and acetone namely I, 
II, III, were obtained by different methods.  All the chemicals used during the preparation 
were purchased from Sigma Aldrich and used as received. 
Form I and II Quercetin-Pyridine solvates 
Form III Quercetin-THF solvate  
Form IV Quercetin-Acetone solvate 
 
Table 3.1 Solvates of Quercetin 
 
 
 
3.3.1 Form I and Form II (Pyridine solvates of Quercetin) 
 
Synthesis: 34 mg of quercetin dihydrate (purchased from Sigma Aldrich and used as 
received) was dissolved in 5ml of Pyridine; this solution was layered with 4 mL of water 
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and refrigerated. After 4 hours golden yellow crystals were produced (yield- 25mg). The 
crystallization experiment was conducted in an unmodified atmosphere and the solvents 
were dried by standard methods prior to use. mp-314 °C. 
                                           
Figure 3.5  Single crystal of quercetin-pyridine solvate 
 
The attempts to get pure crystals of quercetin using pyridine solvate resulted in two 
different forms of quercetin-pyridine solvate namely Form I and Form II. The Form I in 
due course of time transforms to Form II. The crystal structure of Form I reveals that two 
molecules of pyridine hydrogen bond to each molecule of quercetin. The quercetin 
molecules don’t exists as a dimer as found in its dihydrate form (FEFBEX01). But the 
quercetin molecules forms a cyclic pattern, described by Etter’s115 graph set R22 (8). The 
cyclic pattern includes heterosynthons such as OH…CO (D = 2.724 Å) and OH…OH (D = 
2.914 Å). Where as the crystal structure Form II reveals that quercetin molecules exists as 
dimer as found in quercetin dihydrate (FEFBEX01). But the only difference being that in 
FEFBEX01 the dimer includes OHb and the carbonyl moiety whereas in Form II the 
dimer includes OHc and the carbonyl moiety (D = 2.749 Å) and the OHb is just involved 
in the intramolecular hydrogen bonding (D = 2.608(3) Ao). Figure 3.6 represents the 
hydrogen bonding in Form I and Form II. The R22 (8) graph set in Form I and the 
quercetin dimer in Form II are circled in the figure. 
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                                 (a)                                                              (b) 
Figure 3.6 (a) Hydrogen bonding in Form I (b) Hydrogen bonding in Form II 
 
The dihedral angle between the planes containing the rings A, C and ring B for form I 
and Form II are 21.11o and 23.71o respectively. These angles are higher than that is found 
in FEFBEX01 (8.10o). This indicates that quercetin molecules in Form I and II are not 
that planar as in FEFBEX01 (quercetin dihydrate).  
         
 
                                  (a)                                                                (b) 
Figure 3.7 The dihedral angles in From I (a) and Form II (b) 
 
The presence of quercetin-pyridine solvate in two different forms indicates that quercetin 
exhibits polymorphism.65 The CSD search has no entries for the crystal structure of 
polymorphic quercetin but the literature searches reveal that quercetin exhibits 
polymorphism.116-119 The Form II could be most stable than Form I because according to 
Ostwald’s step rule134, 135 which states:  “In general it is not the most stable but the least 
stable polymorph that crystallizes first”. In both the forms the pyridine molecules 
hydrogen bond to OHa and OHe of quercetin molecules. The hydrogen bond distances for 
the OHa…Narom and OHe…Narom in From I are 2.705 Å and 2.677 Å respectively whereas 
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for Form II it is 2.765 Å and 2.64 Å. The distances are in accordance with the distance 
ranges found in CSD as discussed in Chapter 2. Overall supramolecular hydrogen 
bonding in Form I results in 2D tape and in Form II it results in a 2D sheet. Desolvation 
occurs when the crystals are heated at 150oC for 10 min and they become amorphous. 
The amorphous powder could be pure quercetin as it decomposes at 316oC which 
coincides with the literature value.120 
3.3.2 Form III (THF solvate of Quercetin) 
 
Synthesis: 34 mg of quercetin dihydrate (purchased from Sigma Aldrich and used as 
received) was dissolved in 5ml of THF; this solution was layered by 4 mL of hexane and 
refrigerated. After 4 days golden yellow crystals in the form of plates were produced 
(yield-20.5mg). The crystallization experiment was conducted in an unmodified 
atmosphere and the solvents were dried by standard methods prior to use.  mp 316 °C. 
 
                                      
 
Figure 3.8 Single crystal of quercetin-THF solvate (Form III) 
 
 
The crystal structure reveals that there are three THF molecules in the asymmetric unit. 
Two of the THF molecules are involved in the formation of supramolecular network with 
the quercetin molecules and the third distorted THF molecule just act as a guest. All the 
hydroxyl and the carbonyl groups of quercetin and the THF molecules are involved in 
hydrogen bonding. In Form III also quercetin exists as a dimer (circle in Fig 3.9) with a 
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bond distance of 2.749(3) Ao similar to that found in Form II (quercetin-pyridine solvate) 
with hydrogen bond distance of 2.749 Å (OH…CO). Figure 3.9 compares the hydrogen 
bonding in Form II and III. The dimer in Form III can also be described as R22 (10) graph 
set.115
            
Figure 3.9 Comparison of hydrogen bonding in Form III (left) with that of Form II (right) 
 
Desolvation of Form III crystals occurs after 15-20 minutes when they are taken out from 
the mother liquor and leaves the system amorphous and the decomposition temperature of 
the powder coincides with that of quercetin.120 
 
3.3.3 Form III (Quercetin-Acetone solvate) 
 
Synthesis: 34 mg of quercetin dihydrate and 13.3 mg of caprolactam were dissolved in 
5ml of acetone and the refrigerated for 3 days. Golden yellow crystals of solvate III were 
obtained wherein quercetin and acetone were in 1:1 stoichiometric ratio (yield-20mg). All 
the chemicals used during the preparation were purchased from Sigma Aldrich and used 
as received. The crystallization experiment was conducted in an unmodified atmosphere 
and the solvents were dried by standard methods prior to use. mp 316oC.  
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 Figure 3.10 Crystals of Quercetin-Acetone solvate (Form III) 
 
The crystals of solvate III were obtained during an attempt to prepare the cocrystal of 
quercetin and caprolactam by using acetone as a solvent. In Form III also quercetin exists 
as a dimer, but this dimer is formed by OHd and OHe of quercetin molecule form strong 
with hydrogen bond distance of 2.754 Å which falls well with in the range for alcohol-
alcohol supramolecular homosynthon as discussed in Chapter 2. Figure 3.11 represents 
the dimer that is formed in Form III. All hydroxyls and the carbonyl groups of quercetin 
participate in the hydrogen bonding.  Further, OHe of both quercetin molecule hydrogen 
bonds with OHd of adjacent quercetin molecule with OH…OH interaction (D = 2.765 Å) 
and the OHd hydrogen bonds to the carbonyl group of another adjacent quercetin 
molecule and forms a strong OH…O hydrogen bond (D = 2.682 Å). 
 
 
Figure 3.11 Hydrogen bonding in Form III (Acetone molecules colored red) 
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The OHa of each quercetin molecule is bifurcated in hydrogen bonding with acetone 
molecule forming OH…O hydrogen bond (D = 2.596 Å) and OH…OH supramolecular 
homosynthon with adjacent OHa quercetin molecules (D = 2.750 Å). All the hydrogen 
bond distances mentioned above fall well with in the range of distances found in CSD as 
discussed in Chapter 2. The overall hydrogen bonding results in a crisscross grid network 
as represented in Figure 3.12.                                           
                                                                        
          
Figure 3.12 Representation of crisscross grid network in Quercetin-Acetone solvate 
(Space fill model) 
 
3.3.4 Discussions 
 
The attempts to obtain the pure crystals of quercetin from quercetin dihydrate resulted in 
the formation of new forms namely, Form I, Form II, Form III and Form IV. The Form I 
and Form II are the polymorphs of quercetin whereas, the Form III and IV are the 
solvates of THF and acetone respectively. The quercetin molecule exists as dimer in 
Form II and III similar to that of quercetin dihydrate (FEFBEX01)90 where as such kind 
of dimer is absent in Form I. Hydrogen bonding in Form I and II results in the formation 
of linear tapes where as the Form III results in cross grid network. Desolvation occurs for 
Form II after 5-10 minutes when the crystals are taken out of the mother liquor and an 
amorphous powder is obtained where as, the Form I and III are pretty stable in absence of 
mother liquor. In order to get rid of the solvent molecules in Form I and III, the crystals 
were heated at 150 and 55 oC respectively. The amorphous powders from all the three 
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forms were analyzed by DSC and melt temp separately and it was found that in all the 
three cases the powder decomposes at 328 oC, that exactly coincides with the 
decomposition temperature of quercetin. The amorphous form obtained could be pure 
quercetin, but this could not be confirmed as the crystals of pure quercetin were not 
produced by other means. 
3.4 Cocrystals of Quercetin   
 
Crystal engineering of quercetin lead to the generation of two novel cocrystals namely 
Cocrystal I and II with caffeine and isonicotinamide were obtained by slow evaporation. 
The functional groups that are more likely to undergo hydrogen boning in quercetin are 
the hydroxyls and the carbonyl. These functional groups were utilized to target the 
various functional groups in caffeine and isonicotinamide such as the nitrogen in the 
imidazole ring and the imide groups in caffeine and the aromatic nitrogen and the amide 
groups in isonicotinamide. The CSD searches (Chapter 2) reveal that the polyphenols are 
more likely to form supramolecular synthons with functional groups like carbonyl and 
aromatic nitrogen. The percentages obtained for OH…Narom and OH…CO supramolecular 
heterosynthons in the CSD searches are 84.8% and 74.4% respectively.  
3.4.1 Quercetin- Caffeine- Methanol cocrystal solvate 
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Figure 3.13 The asymmetric unit of 1:1:1 cocrystal solvate of quercetin, caffeine and methanol 
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Synthesis: 68 mg of quercetin dihydrate and 38 mg of caffeine were dissolved in 
approximately 5 mL of methanol and heated until a clear solution was obtained. Slow 
evaporation of this solution in refrigerator resulted in 1:1 crystals after 3 days (yield- 30 
mg). All the chemicals used during the preparation were purchased from Sigma Aldrich 
and used as received. All crystallization experiments were conducted in an unmodified 
atmosphere and the solvents were dried by standard methods prior to use. mp: 246°C. 
 
Figure 3.14 Single crystal of quercetin-caffeine-methanol cocrystal solvate (Cocrystal I) 
 
 
he crystal structure reveals that the imide group and the aromatic nitrogen of caffeine 
are the functional group that interacts with the hydroxyl groups of quercetin. Caffeine 
molecules interact with quercetin molecules via the formation of OHc Narom and 
OHa CO supramolecular heterosynthons. The former supramolecular heterosynthon is 
formed by the interaction of OHc quercetin and the aromatic nitrogen of the imidazole 
ring in caffeine (D = 2.821(3) A ) and the latter results due to the hydrogen bonding 
between OHa of quercetin and the CO moiety of the imide group of caffeine (D= 2.716(3) 
A ). The carbonyl in the caffeine molecule hydrogen bonds to the methanol molecule 
(D=2.712(3) A ). All the above distances are in accordance with the OH O synthon and 
OHc Narom distance ranges found in CSD as discussed in Chapter 2.  
T
…
…
o
o
o …
…
 Figure 3.15 Intermolecular interactions in the 1:1:1 cocrystal solvate of quercetin, caffeine and 
methanol (colored green) 
 
 
Adjacent quercetin molecules interact by utilizing some of the remaining hydrogen 
bonding sites as follows: trifurcation of the OHb moiety of quercetin molecules through 
supramolecular homosynthon and OH…CO supramolecular heterosynthon. The OH…OH 
supramolecular homosynthon is formed between the OHb of quercetin molecules and 
OHd and OHe of adjacent quercetin molecules (D = 2.774(3) Ao, 2.847(3) Ao 
respectively). OHb is also engaged in OH…CO intramolecular heterosynthon (, D = 
2.602(3) Ao). The bond distances fall in the range found in the CSD searches for the 
respective synthons as discussed in Chapter 2. These hydrogen bond interactions afford a 
supramolecular sheet that stacks up.  These sheets are further connected via the 
interaction of methanol molecules with OHe moieties of quercetin molecules through 
OH…OH supramolecular homosynthons (D = 2.633(3) Ao). The overall effect of the 
hydrogen bonding results in the formation of a network where the methanol could be 
described as a guest although as shown in Figure 3.16. 
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 Figure 3.16 Illustration of sheets generated in the cocrystal 1. 
 
 
3.4.2   Quercetin-Isonicotinamide 
 
Figure 3.17 The asymmetric unit of the1:1 quercetin – isonicotinamide cocrystal 
 
Synthesis: 67.6 mg of Quercetin dihydrate and 24.6 mg of isonicotinamide were 
dissolved in approximately 5 mL of methanol and heated until a clear solution was 
obtained. Slow evaporation of this solution in refrigerator resulted in 1:1 crystals after 2 
days (yield-31.5mg). All the chemicals used during the preparation were purchased from 
Sigma Aldrich and used as received. The crystallization experiment was conducted in an 
unmodified atmosphere and the solvents were dried by standard methods prior to use. 
mp: 256-260°C.  
  
Figure 3.18  Single crystal of quercetin-isonicotinamide cocrystal (Cocrystal 2) 
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The aromatic nitrogen and the carbonyl moiety of the amide group and the carbonyl 
group in quercetin acts as hydrogen bond acceptors where as all the hydroxyl groups of 
quercetin can act as hydrogen bond acceptors/donors. Isonicotinamide molecules interact 
with quercetin molecules via, CO…OH and NH…OH supramolecular heterosynthons and 
OH…OH supramolecular homosynthons. One of the two hydrogen atoms in the amino 
moiety of the isonicotinamide hydrogen bonds to the carbonyl group of adjacent 
quercetin molecules and the other hydrogen atom interacts with OHd of a different 
quercetin molecule giving rise to NH…CO (D = 3.018(4) Ao) and NH…OH (D = 3.028(4) 
Ao) supramolecular heterosynthons, respectively. These distances are in accordance with 
the distance ranges found in the CSD search for amides in Chapter 2. The carbonyl of the 
amide moiety hydrogen bonds to OHe quercetin molecules whereas the Narom atom of the 
isonicotinamide molecule interacts with OHa of quercetin molecules and thereby 
generates CO…OH (D = 2.607(3) Ao) and Narom…OH (D = 2.684(3) Ao) supramolecular 
heterosynthons respectively. The distances fall within the range found in CSD as 
discussed in Chapter 2.  
 
Figure 3.19 Intermolecular interactions in the 1:1 Quercetin-Isonicotinamide cocrystal. 
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The OHd & OHe moieties of two quercetin molecules and the amide moieties and the syn  
hydrogen atoms of the amino group of two isonicotinamide molecules form a four 
component assembly composed of two R22 (8) and one R22 (10) supramolecular synthons 
(Etter’s graph set).115 Both the patterns result in R44 (18) graph set as represented in 
Figure 3.6. 
                                 
Figure 3.20 Illustration of R44 (18) graph set in quercetin and isonicotinamide cocrystal. 
 
 
The R22 (8) graph set is formed by two quercetin molecules and one isonicotinamide 
molecules which includes OH…CO supramolecular heterosynthon formed between OHe 
moieties and the carbonyl groups of isonicotinamide molecules (D = 2.607(3) Ao. The 
R22 (10) supramolecular synthon occurs between two quercetin molecules in which 
OH…OH supramolecular homosynthons are formed between OHd & OHe groups of two 
quercetin (D= 2.765(3) Ao). The dimer [R22 (10)] is formed between two quercetin 
molecules remains intact and the exterior hydrogen bonding sites are utilized in the 
hydrogen bonding with N-H of isonicotinamide (D 3.028(4) Ao). The bond distances 
found in the supramolecule are in accordance with the distances found in CSD for the 
respective synthons as discussed in Chapter 2.  
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3.4.4 Discussions 
 
Crystal engineering has lead to the generation novel cocrystals of quercetin and thus 
confirms that flavonoids are capable of generating novel cocrystals with pharmaceutically 
acceptable molecules such as caffeine and isonicotinamide. As caffeine and 
isonicotinamide have no solubility problems whereas caffeine has problem with physical 
stability against hydration. The CSD reveals that there are 17 entries for the cocrystals of 
caffeine. There are also evidences which indicate that cocrystallization of caffeine with 
suitable cocrystal formers (CCF) overcome the hydration problem.121 Even 
isonicotinamide 122 seems to be a good CCF as there are cocrystals of it in the literature. 
The CSD statistics as discussed in Chapter 2 reveals that aromatic nitrogen and carbonyl 
functional groups are good acceptors to hydrogen bond with the hydroxyls of 
polyphenolic compounds. Therefore caffeine and isonicotinamide (isomer of 
nicotinamide, known as niacin) 123 stand as suitable CCFs for cocrystallization and are 
pharmaceutically acceptable molecules. Thus crystal engineering allows one to choose 
complementary components for polyphenolic compounds for designing supramolecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. HESPERETIN 
 
 
Hesperetin (RS-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-
benzopyran-4-one) is a naturally occurring flavanone which is unique among the others as it 
is the only one which is faintly sweet while most of the flavonoids are tasteless or bitter.124  
Hesperetin is the aglycone form of hesperedin which is abundantly present in citrus fruits. 
Animal studies have shown that hesperetin has very good anti-inflammatory properties.125, 111
 
 
Figure 4.1 Structure of hesperetin (hydrogen are not included) 
 
4.1 Description  
 
Hesperetin (Mol.Wt 302.27 g/mol) is a bioflavonoid that is present in the plants in its 
glycoside form (hesperedin). We have discussed earlier in Chapter 1, how glycoside forms of 
flavonoids are more soluble that the aglycone form. Hesperedin is more soluble than 
hesperetin because of the sugar ring attached to it.126 It is a phenolic antioxidant127, 
antiallergic128, and antimutagenic129. It may scavenge the reactive oxygen species as 
superoxide anions and may protect against peroxidation. Studies on rats have shown that 
hesperetin helps in reducing the cholesterol by the inhibition of 3-hydroxy-3-ethylglutaryl 
coenzyme A.130 In vitro studies have also shown that hesperetin has some anti cancer activity 
too.131 
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4.2 Strategy for Crystal Engineering of Hesperetin 
 
Hesperetin has similar structure to that of quercetin, the difference being rings B and C. In 
ring B there is a methoxy group instead of a hydroxyl and saturated ring C. Figure 4.2 
represents the structure of hesperetin with its 3 rings A, B, C. The hydroxyl groups are 
labeled a, b and c. The hesperetin molecule has two hydroxyl groups on ring A and one on 
ring B act as hydrogen bond acceptors and/or donors. Hesperetin has also has an ether and 
carbonyl (ketone) moieties on ring C that can act as hydrogen bond acceptors. 
O
OCH3
OHc
OHb
OHa
O
 B
CA
 
 
Figure 4.2 Illustration of rings in Hesperetin 
 
 
The data available in the CSD reveals that there are two crystal structures of hesperetin 
discovered so far, one is the pure hesperetin (YEHROS) 132 and the other is the monohydrate 
form (FOYTOC).133
          
(a) (b) 
 
Figure 4.3 Hydrogen bonding in (a) Hesperetin (b) Hesperetin monohydrate 
 
Figure 4.3 represents the hydrogen bonding in both the available forms of hesperetin as a 
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racemate and monohydrate. Hesperetin molecule in YEHROS is not a planar molecule as 
represented in Figure 4.4 (a).  
 
(a) YEHROS 
 
(b) FOYTOC 
Figure 4.4 Illustration of the dihedral angles (blue plane contains rings A and C; 
 red plane contains the ring C). 
 
The two rings A and C lie in the same plane and the ring B lies in the other plane with a 
dihedral angle of 53.59o. Whereas, in FOYTOC hesperetin adopts almost a planar 
conformation while the conformation in YEHROS seems to be more favorable as there is less 
repulsive steric hindrance between the rings with a dihedral angle of 2.91o as represented in 
Figure 4.4 (b).133 
4.2.1 Hesperetin-Isonicotinamide cocrystal (Cocrystal 3) 
 
 
 
Figure 4.5 The asymmetric unit of hesperetin:isonicotinamide 1:1 cocrystal 
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Synthesis: 60 mg of Hesperetin and 24.6 mg were dissolved in approximately 5 mL of 
ethanol and heated until a clear solution was obtained. Slow evaporation of this solution in 
refrigerator resulted in 1:1 crystals after 5 days. All crystallization experiments were 
conducted in an unmodified atmosphere and the solvents were dried by standard methods 
prior to use. All chemicals were purchased from Aldrich and used as obtained. m.p 172-
176oC. 
 
 
 
Figure 4.6 Single crystal of hesperetin-isonicotinamide cocrystal 
 
 
Crystallization of hesperetin with isonicotinamide resulted in a 1:1 cocrystal. In the 
isonicotinamide molecule, the aromatic nitrogen and the carbonyl moiety of the amide group 
act as hydrogen bond acceptors. The two hydrogen atoms of the amino group of the amide 
moiety act as the hydrogen bond donors. The X-ray crystal structure reveals the existence of 
a supramolecular homosynthon (amide dimer) formed by the interaction of two 
isonicotinamide molecules. This results in a graph set notation115 R22 (8) with O---Narom 
interaction as represented in Figure 4.8 with bond distance of 2.868(3) Ao that fall well with 
the range found in CSD in Chapter 2. The supramolecular synthon formed in the cocrystal 
includes OH---N hydrogen bond between the nitrogen atom of isonicotinamide and the OHa 
of the adjacent hesperetin molecule with an O---N bond distance of 2.623(2) Ao. OHa is 
further bifurcated as it forms a hydrogen bond with the anti N-H of the isonicotinamide 
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dimer with an N---O bond distance of 3.031(3) Ao. The amide dimer remains intact and as 
observed in the crystal structure of pure isonicotinamide. 
 
Figure 4.7 Overall hydrogen bonding in the Hesperetin-Isonicotinamide 1:1 cocrystal 
 
The hesperetin molecules lie opposite to each other around the crystallographic inversion 
center as represented in Figure 4.8. The adjacent hesperetin molecules interact via OH---
CO utilizing the hydroxyl moieties on ring B with a bond distance of 2.720(2) Ao. There is 
also intramolecular hydrogen bonding between the carbonyl (ketone) group on ring C and 
the OHc with a bond distance of 2.584(2) Ao. All the hydrogen bond distances found in 
hesperetin and isonicotinamide falls well with in the expected as discussed in Chapter 2. 
 
 
Figure 4.8 Illustration supramolecular synthons in the cocrystal 3. 
 
Figure 4.7 represents the how the hesperetin and isonicotinamide molecules arrange 
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themselves in the crystal lattice. The hydrogen bonding in the cocrystal 3, the hesperetin 
molecules form a one dimensional tape along Z-axis and these tapes are connected through 
centrosymmetric amide dimers formed by isonicotinamide molecules forming a two 
dimensional sheets with cavities (31 x 10 Å2).  
                                         
Figure 4.9 The cavity formed in hesperetin:isonicotinamide cocrystal. 
 
The cavities are filled by similar sheets and its eight fold interpenetrated. The overall 
hydrogen-bonding pattern is that of a zigzag 2-D sheet with interpenetration and it means that 
all hydrogen bond donors and acceptors in both molecules are satisfied as shown in Figure 
4.10. 
 
Figure 4.10 Illustration of 8-fold interpenetrated network formed in Cocrystal 3 
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The hesperetin molecules maintain the angular conformation similar to what is observed in 
pure hesperetin crystal structure (YEHROS). The dihedral angle observed for hesperetin 
molecules in the cocrystal between the planes containing rings A, C and ring B is greater by 
24.2o than found YEHROS. The hesperetin molecules are more stable in angular 
conformation as the steric hindrance is reduced. Figure 4.11 represents the dihedral angle 
between the planes of the rings in hesperetin molecule.  
 
Figure 4.11 Illustration of dihedral angle in hesperetin molecules (red plane contains rings 
 A and C; blue contains ring C) 
 
 
4.2.2 Hesperetin-Nicotinic acid cocrystals 
 
 
 
 
Figure 4.12 Hesperetin – Nicotinic acid 1:1 zwitterion cocrystal (Form I) 
 
Synthesis: 60 mg of Hesperetin and 24.6 mg of nicotinic acid were dissolved in 
approximately 5 mL of methanol and heated until a clear solution was obtained. Slow 
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evaporation of this solution in refrigerator resulted in 1:1 crystals after 5 days. All 
crystallization experiments were conducted in an unmodified atmosphere and the solvents 
were dried by standard methods prior to use. All chemicals were purchased from Aldrich and 
used as obtained. m.p 198-204 oC. 
 
 
Figure 4.13 Single crystals of hesperetin-NA cocrystals. 
 
Crystallization of hesperetin with nicotinic acid results in two1:1 cocrystals in which the 
nicotinic acid exists as a zwitterionic state, Form I contains only one of the enantiomer of  
R-hesperetin (Cahn-Ingold-Prelog priority rules) and converts to Form II which contains both 
forms of (+) hesperetin (Cahn-Ingold-Prelog priority rules) crystallizes with nicotinic 
zwitterion. As Form I contains only one of the enantiomer of hesperetin in the crystal 
structure it is called as the racemic conglomerate and Form II is the racemate of hesperetin. 
During the crystallization process both the cocrystals were generated in the same vial and the 
reproduction of the Form I cocrystal was not achieved. This indicates that Form I is 
kinetically more favored and Form II is thermodynamically.  Figure 4.13 represents the 
overall hydrogen bonding in cocrystal Form I. The crystal structure of Form I reveals the 
existence of nicotinic acid (NA) as a zwitterionic species in the cocrystal, which is not an 
amino acid. The zwitterion of NA can be confirmed by the following structural information: 
a) The C-O bond distances in the carboxylate ion were found to be 1.241 Å 7& 1.250 Å and 
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the corresponding C-N-C (protonated pyridine) bond angle equal to 121.54o. Where as, the 
C-O & C=O bond distances and the C-N-C bond angle in NA are 1.217Å &1.289 Å and 
117.65o respectively. 
 
Figure 4.14  Overall hydrogen bonding in the hesperetin Form I cocrystal. (Blue color- R-Hesperetin) 
 
 
Pure NA forms a linear tape where they are hydrogen bonded to each other in a head to tail 
fashion with a bond distance of 2.666 Å. Similar kind of tape is also present in Form I 
cocrystal with hydrogen bond distance of 2.604 Å. Figure 4. 15 represents the tapes that are 
formed in NA in pure NA (a) and in Form I cocrystal (b) respectively. 
 
(a) 
               
(b) 
Figure 4.15 Illustration of hydrogen bonds in NA: a) NA in pure form b) NA in the cocrystal, hesperetin 
molecules are deleted for clarity. 
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The CSD search for the cocrystals of NA reveals that there are only two entries with ref 
codes AWIDEB136 and SESLIM.137 The two cocrystals were made by using 3,5-
dinitrobenzoic and 4 amino benzoic acid respectively. The crystal structure of SESLIM 
reveals that NA acid form a molecular tape similar to that found in pure NA and Form I 
cocrystal. The other modes by which the remaining hydrogen bonding sites are exploited 
includes O---O (D = 2.504 Å) interaction between NA and the OHa of hesperetin molecule. 
The hesperetin molecules are interconnected via OH…OH supramolecular hydrogen bonding 
(D = 2.867 Å) and forms linear tapes that sandwich the NA molecular tapes. There is weak 
hydrogen bonding between the OHb of hesperetin molecule with the ether group of the other 
hesperetin molecules with a bond distance of 3.001 Å. All the hydrogen bond distances fall 
in the ranges found in the CSD as discussed in Chapter 2. In Form I, the hesperetin changes 
in conformation adopts almost a planar conformation similar to that in hesperetin 
monohydrate (FOYTOC) with a dihedral angle of 4.68o between the planes containing the 
rings A, B and C. Figure 4.16 represents the dihedral angle. 
 
                             
 
 
Figure 4.16 Representation of dihedral angle between the rings. (red plane contains rings A and C, blue 
plane contains ring B) 
 
The crystal structure of the Form II reveals (Cahn, Inngold and Prelog rules) that hesperetin 
crystallizes out as a racemate, is a result of thermodynamically favored product. The NA 
zwitterions hydrogen bond with each other in a head-to-tail fashion and thereby form chains 
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that are sandwiched by chains of hesperetin molecules. The crystal is still polar as the head-
to-tail chains of NA zwitterions are parallel throughout the crystal structure. The three chains 
are linked by lateral hydrogen bonds and therefore form a network that could be described as 
a supramolecular tape as a represented in Figure 4.17. The molecular structure of hesperetin 
as it exists in Form II reveals that one of the three hydroxyl groups engages in an 
intramolecular hydrogen bond with the carbonyl moiety. All the hydrogen bonds formed in 
both the forms have their distances that fall well with in the bond ranges obtained in the CSD 
searches as discussed in Chapter 2. 
 
 
 
Figure 4.17 The hydrogen bonding in the hesperetin Form II cocrystal (yellow and maroon: NA 
molecules, (+) hesperetin: blue, (-) hesperetin) green) 
 
 
In Form II, the hesperetin maintains the almost planar conformation as found in Form I but it 
is slightly greater. In Form I it is 4.69o and in Form II it is around 11.38o.  
                
 
    
Figure 4.18 The dihedral angle formed between the planes of rings A, C and ring B in Form II 
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4.2.4 Discussions  
 
 
Crystal engineering has lead to the generation novel cocrystals of hesperetin with 
pharmaceutically acceptable molecules such as isonicotinamide and nicotinic acid (NA). 
For the first time crystal engineering has been applied to generate cocrystals of 
Flavonoids. As we discussed earlier in Chapter 2 that compounds containing aromatic 
nitrogen are more likely to form hydrogen bond with phenolic –OH groups.  
Both isonicotinamide and NA have aromatic nitrogen and make them good cocrystal 
formers for the cocrystallization of hesperetin. In addition to aromatic nitrogen 
isonicotinamide and NA have amide and acid groups respectively which are capable of 
forming hydrogen bonds with hesperetin. The CSD search reveals that there are almost 
26 cocrystals of isonicotinamide. Among the 26 cocrystals three are with polyphenols 
such as phloroglucinol,138 hydroquinone,138 and resorcinol.138 NA has two cocrystals 
dinitrobenzoic136  acid and aminobenzoic acid.137 Thus isonicotinamide and NA seem to 
be good cocrystal former (CCF) for cocrystallization.  
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5. DISSOLUTION STUDIES OF COCRYSTALS 
 
 
Most of the active pharmaceutical ingredients (APIs) are administered in the solid state as 
part of an approved dosage type like tablets, capsules, etc as these are the convenient and 
compact format to store a drug.70 The absorption of all the forms of a drug depends on its 
physical properties.139 There are examples of drugs that are commercially available that 
suffer problems related to solubility, dissolution rate and absorption in the neutral form. 
These entire problems thus restrict the bioavailability of drugs. In this context the 
application of crystal engineering to the field of pharmaceutics provides a solution. It has 
intensified the research in the pharmaceutical industries as it offers a means to alter the 
solubilities of drugs by the discovery of new crystal forms there by improving the 
bioavailability.140, 141 The new forms include polymorphs, solvates, salts, hydrates and 
cocrystals. There are evidences where in it is proved that drugs that are commercially 
available, such as fluoxitine HCl (Prozac*)86, Itraconazole (Sporanox*)75 with low 
solubility show a drastic improvement in the solubilities via cocrystallization. But not all 
cocrystals show improved properties, and they are not a panacea for all problems.  
                     For example the cocrystals67 forms of Fluoxetine hydrochloride, an anti 
depressant drug, with a series of acids, has shown variations in its solubility when 
compared to the pure API. For fluoxetine HCl: succinic acid cocrystal an approximate 3-
fold increase in the dissolution of the API relative to fluoxetine HCl, the cocrystal of 
fluoxetine HCl: benzoic acid dissolves at a rate that is approximately half of the rate for 
the API alone, while the dissolution rate for fluoxetine HCl: fumaric acid cocrystal is 
roughly similar to that of fluoxetine HCl. These results reveal that, by cocrystallizing an 
API with different guest molecules, it is possible to increase or decrease the dissolution 
rate of the API or to leave the effective dissolution rate essentially unchanged. The Figure 
5.1 represents the results of dissolution studies carried out for various cocrystals of 
fluoxetine HCl. 
 
 
 
 
Figure 5.1   Powder dissolution profiles for (1), (2), (3), and (4) in water at 20 °C. 
 
 
Another example of API that forms cocrystals is Itraconazole (Sporanox), a low 
solubility drug that is available commercially in the amorphous form. The dissolution 
studies of the cocrystals of Itraconazole drug with carboxylic acids show a wide range of 
solubilities ranging from 4-20 fold than that of the crystalline form of API. 
 
 
Figure 5.2  Dissolution profiles into 0.1 N HCl at 25 °C for Sporanox beads and the cocrystals 
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The carbamazepine (CBZ): saccharin cocrystal is also an appropriate example in this 
context. CBZ, commercially available as Tegretol, is another example of low soluble 
drug.142 The CZB:saccharin cocrystal has better solubility when compared to CBZ 
dihydrate and pure CBZ. The cocrystal even offers more stability (cocrystal is more 
stable than pure CBZ for more than 24hrs) to CBZ in the cocrystal. Figure 5.3 compares 
the plasma concentration of CBZ and the cocrystal in fated beagle dogs.  
 
 
Figure 5.3 Average plasma time curves of carbamazepine concentrations (±SEM) from a cross-over 
experiment in fasted beagle dogs (n = 4) given oral doses of 200 mg of the active drug as Tegretol 
tablets and co-crystal 
 
5.1 Dissolution experiments of quercetin and hesperetin cocrystals 
 
Dissolution is a characterization test commonly used by the pharmaceutical industry to 
guide formulation design and control product quality.143 It is also the only test that 
measures the rate of in vitro drug release as a function of time, which can reflect either 
reproducibility of the product manufacturing process or, in limited cases, in vivo drug 
release. The common analytical methods used for quantifying drug release in dissolution 
tests are: spectrophotometric, chromatographic, mass spectrometric, and 
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potentiometric.144 The UV/VIS spectrophotometric method has been the traditional 
analytical method for dissolution testing. A compound will exhibit absorption in the UV 
region if it contains one or more chromophores, such as aromatic nitro, azoxy, nitroso, 
carbonyl, or azo groups. For quantitation of any given drug, the desired absorption (A) 
should be 0.3–1.0. In the UV absorption spectra of flavonoid, there are generally two 
main absorption bands, band I (300–400nm) and band II (240–300 nm) which are 
associated with the absorption of the cinnamoyl system and the absorption of the benzoyl 
moiety in the molecules respectively.145, 146 The two absorption bands are more sensitive 
to the environment of pH due to the weak acidity of the phenolic hydroxyl groups of 
flavonoid. In the UV absorption spectra of hesperetin in ethanol, the main absorption 
peak is assigned as band II, centered in about 290 nm, and there is only a weak broad 
shoulder peak in about 330 nm.145, 147 The reason for this is because the B ring of 
hesperetin is not conjugated with the carbonyl group in ring C. Whereas quercetin has 
two bands at 255 nm and 374 nm respectively. The band II for quercetin is broader than 
band I and this is due to the conjugation of ring B with ring C.  
            As quercetin and hesperetin did not show any UV absorbance spectrum in water 
raised a situation to look for a suitable solvent in which these compounds are soluble and 
suitable for the dissolution studies. Most of the flavonoids are soluble in alcohols; 
therefore a mixture of solvent system consisting of 1:1 ethanol/water (V/V%) was 
adopted in order to carry out the dissolution experiments. Figure 5.4 represents UV 
spectrum of quercetin and hesperetin in 1:1 ethanol/water (V/V%) solvent system.        
 
 
 
Figure 5.4 UV spectrums of Quercetin and Hesperetin in 1:1 Ethanol/Water (V/V%)  
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tandard
For cocrystals 2, 3, 4 the dissolution were carried out in 50 % EtOH/Water (v/v) mixture. In 
order to avoid the interference from methanol in the quercetin:caffeine:methanol cocrystal 
solvate, methanol/water solvent system was employed. A 3:2  methanol/water (V/V%) 
solvent system was used for the dissolution of cocrystal 1.  The dissolution study for 
cocrystal 1 was carried at 400nm as caffeine did not absorb at this wavelength and did not 
interfere with the determination of concentration of quercetin. In the similar way the 
wavelengths for the dissolution of cocrystals 2, 3, 4 (cocrystal 2 = 360nm, cocrystal 3 & 4 = 
300nm) were selected in such way that the interference of the cocrystal formers was not 
observed while determining the concentration of respective flavonoids. The standard 
calibration curves all the cocrystals were plotted by preparing the standard solutions of the 
cocrystals in their respective solvent systems.  For the bulk powder dissolution of cocrystals 
1-4 the powder was sieved using ASTM s  sieve in order to get the particle sizes 
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was 
ranging between 53 - 75 µm.  All the experiments were carried at room temperature in 3 sets 
for each cocrystal in order to have reliability. Approximately 900mg of the sample was added 
to the beakers containing 80mL of solvent mixture and the resulting slurry was stirred at 200 
rpm with the help of spinning vane on a stir plate. At regular intervals of time an aliquot 
drawn out from the beaker and it was filtered using a 0.25 µm nylon filter. Appropriate 
amount of the resulting solution was diluted with the solvent mixture and then the UV 
absorption was recorded.   
 
5.2 Dissolution study of Quercetin:Caffeine cocrystal (Cocrystal 1) 
 
The dissolution studies of cocrystal 1 (solvated and desolvated forms) in water did not show 
any improvements in the solubility of quercetin. Therefore, the dissolutions of methanol 
solvate of quercetin-caffeine cocrystal (KP05) and desolvated cocrystal were carried out in 
3:2 methanol/water (V/ V %) solvent system. The Figure 5.4 represents the comparison of 
the dissolution of quercetin dihydrate with the methanol solvate and desolvated cocrystals. It 
is evident from the Fig 5.5 that there is an approximate 6-fold improvement in the solubility 
of quercetin in the methanol solvate cocrystal and 21-fold improvement in the desolvated 
cocrystal in 3:2 methanol/water (V/ V %) solvent system when compared to quercetin 
dihydrate. The solubility of quercetin in the desolvated cocrystal (amorphous form) has much 
better solubility than the solvated cocrystal in the first hour. But, later (after 1 hour) the 
desolvated cocrystal converts to the solvated cocrystal as the solubility goes down and 
coincides with the solvated cocrystal. The dissolution experiment demonstrates that the pure 
cocrystal has better solubility than the solvated cocrystal. Thus, cocrystallization can tailor 
the solubility of a compound and could afford to improve the bioavailability. 
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Figure 5.5 Comparison dissolution profiles of quercetin, methanol solvated cocrystal and the desolvated 
cocrystal in 3:2 MeOH/Water (V/V%) solvent system 
 
 
5.2 Dissolution study of Quercetin-Isonicotinamide (Cocrystal 2) 
 
 
The dissolution quercetin-isonicotinamide cocrystal (KP10) was carried out in 1:1 
ethanol/water (V/V%) solvent system as there was no improvement in the solubility of 
quercetin. It is clear from the Figure 5.5 that the solubility of quercetin in the cocrystal 
reaches the maximum value within the first five minutes and then the solubility goes down 
and gets almost close to that of quercetin dihydrate. The solubility of pure quercetin through 
out the experiment is almost constant this indicates that the solubility of pure quercetin 
reaches the saturation limit within five minutes. The dissolution of quercetin cocrystal with 
isonicotinamide reveals that the solubility of quercetin has been improved 6-folds in 1:1 
ethanol/water (V/V%) solvent system. 
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Figure 5.6 Dissolution profiles of quercetin and quercetin-isonicotinamide (1:1) cocrystal in 1:1 
EtOH/Water (V/V%) solvent mixture 
 
 
5.3 Dissolution study of Hesperetin-Isonicotinamide (Cocrystal 3) 
 
 
The dissolution of cocrystal 3 (KP15) was also carried out in 1:1 ethanol/water (V/V%) 
solvent system as it did not showed any improvement the solubility in water. The solubility 
of pure hesperetin remains constant through out the time. But the solubility of hesperetin in 
the cocrystal increases slowly reaches a maximum value after 40 min and later it deteriorates 
down, if extrapolated probably could reach to the saturated limit similar to that pure 
hesperetin. Figure 5.6 represents the comparison of the concentrations of pure hesperetin and 
hesperetin in the cocrystal plotted against time. This indicates that the solubility of hesperetin  
has been improved 10-12 fold via cocrystallization in 1:1 ethanol/water (V/V%) solvent 
system. 
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Figure 5.7 Dissolution profiles of hesperetin and hesperetin-isonicotinamide (1:1) cocrystal in50 % 
EtOH/Water (v/v) solvent system 
 
 
5.4 Dissolution study of Hesperetin-NA (Cocrystal 4) 
 
 
The dissolution experiment of cocrystal 4 (KP22) reveals that the solubility of hesperetin in 
cocrystal increases tremendously from zero to 3.5 mg/mL of 1:1 ethanol/water (V/V%) 
solvent system within five minutes of the experiment. In the due course of time the solubility 
of hesperetin (cocrystal) decreases reaches around 2 mg/mL after 3 hrs was carried out in 1:1 
ethanol/water (V/V%) solvent system. The Figure 5.7 represents the comparison of the 
dissolution of hesperetin with its cocrystals with isonicotinamide and nicotinic acid. The NA 
cocrystal shows an approximate 5-fold increase in the solubility of hesperetin.  
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Figure 5.8 Comparison of dissolution profiles of hesperetin with its cocrystals 
 
 
5.5 Discussions 
 
 
The application of crystal engineering to the field of nutraceuticals has been demonstrated by 
synthesizing the cocrystals with pharmaceutically acceptable molecules. Incorporating 
pharmaceutically acceptable molecules with the desired target nutraceuticals provides an 
opportunity to tailor the solubilities and thereby generating more chances to improve the 
bioavailability. Crystal engineering plays a vital role in setting up the strategies for selecting 
appropriate nutraceutical:guest combinations that could form complementary hydrogen 
bonds and producing the novel cocrystals.  
                    In order to check whether the cocrystallization has altered the solubility of 
hesperetin and quercetin it was important do the dissolution experiments for the pure 
flavonoids as well as the cocrystals. But owing to the poor solubility of hesperetin and 
quercetin in water has forced to adopt a different solvent for the dissolution of the cocrystals. 
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As most of the flavonoids show good solubility in alcohols, 1:1 ethanol-water solvent system 
was adopted. It is evident from the dissolution experiments that all the cocrystals of 
hesperetin and quercetin showed an improved solubility. Thus confirming the fact that 
cocrystallization offers a potential means to tailor the physical properties of the target 
molecules in the solid state. As the solubility and bioavailability are interdependent, 
cocrystallization could be a better alternative to tailor the solubility, in return the 
bioavailability. 
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6. CONCLUSIONS AND FUTURE DIRECTIONS
 
 
 
The study of crystal engineering remained as an understudied subject until Schmidt’s work 
on topochemical reactions15 popularized it. Later it expanded to larger areas like 
Supramolecular Chemistry.16 In the field of pharmaceutics crystal engineering has excelled 
greatly as it offers a wide range of application to the drug discovery. It has lead to the 
discovery of new forms of drugs as solvates, hydrates, polymorphs58 and cocrystals54 which 
allows handling problems pertaining to the physiochemical properties of drugs such as 
hygroscopicity, solubility and bioavailability.  
                              In case most of the APIs and nutraceuticals these properties can be tailored 
by cocrystallizing pharmaceutically acceptable molecules. In this regard, crystal engineering 
proves to be an efficient tool. It directs the one to select appropriate cocrystal formers to 
generate cocrystals by exploring the non-covalent interactions such as hydrogen bonding. 
                      The flavonoids have many benefits to the human health; the problem lies with 
their solubility and bioavailability that limits their usage.2 Therefore, flavonoids have been 
selected for the research work. The results herein demonstrate the wide range application of 
crystal engineering to generate new forms of quercetin and hesperetin. The utilization of 
crystal engineering to synthesize cocrystals has been demonstrated using the cocrystals of 
quercetin and hesperetin with pharmaceutically acceptable molecules like caffeine, nicotinic 
acid and isonicotinamide. The work also developed new solvent systems for dissolutions 
where, the dissolutions studies in water are not possible. The application of such solvent 
 67  
systems may not be allowed pharmaceutically but could act as templates for other cocrystals 
as the results indicate increase in the solubility of the quercetin and hesperetin via 
cocrystallization. These results could be the subject of future contributions. 
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Appendix A:  
 
1. Crystallographic data and Experimental data for the new crystal forms of 
Quercetin 
 
 
 
  
Form I 
 
Form II 
 
Form III 
 
Form IV 
 
Cocrystal 1 
 
Cocrystal 2 
 
Formula 
 
C25H20N2O7
 
C25H20N2O7
 
C27H26O10
 
C16 5H10O8 75
 
C24H24N4O10
 
C21H16N2O8
 
m.p. (°C) 
 
316 
(decomp) 
 
316 
(decomp) 
 
318 
(decomp) 
 
316 
(decomp) 
 
246 
 
256-260 
 
Mol. Wt. 
 
460.43 
 
460.43 
 
510.48 
 
351.25 
 
528.47 
 
424.36 
Crystal 
System 
 
Monoclinic 
 
Triclinic 
 
Triclinic 
 
Monoclinic 
 
Monoclinic 
 
Triclinic 
Space 
Group 
 
P2(1)/c 
 
P-1 
 
P-1 
 
C2/c 
 
P2(1)c 
 
P-1 
 
A (Å) 
 
16.727(7) 
 
10.188(2) 
 
9.0830(3) 
 
38.192 
 
10.315(2)  
 
4.9780(10)  
 
B (Å) 
 
17.564(8) 
 
10.224(2) 
 
10.858(3) 
 
3.6344 
 
14.853(4)  
 
12.636(3)  
 
C (Å) 
 
6.919(3) 
 
12.082(3) 
 
13.063(3) 
 
21.227 
 
15.229(4)  
 
15.571(3)  
 
Α (°) 
 
90 
 
104.167(4) 
 
102.344(5) 
 
90 
 
90 
 
110.53(3) 
 
Β (°) 
 
91.456(12) 
 
109.081(3) 
 
93.516(4) 
 
104.57(3) 
 
100.667 
 
97.63(3) 
 
Γ (°) 
 
90 
 
107.775 
 
111.149(4) 
 
90 
 
90 
 
99.39(3) 
Volume 
(Å3) 
 
2032.2(14) 
 
1046.3(4) 
 
1255.5(5) 
 
2851.7(10) 
 
2292.9(4)  
 
885.7(3)  
calc 
density 
(mg/cm3) 
 
1.505 
 
1.461 
 
1.350 
 
1.636 
 
1.531 
 
1.591 
 
Solvent 
 
Pyridine 
 
Pyridine 
 
THF 
 
Acetone 
 
Methanol 
 
Methanol 
 
 
1.1 Experimental data for Form I and Form II 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(black) calculated from the single crystal structure of Form I (green) and From II (red) 
and TGA. 
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1.2 Experimental data for Form III 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black) and TGA. 
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1.3 Experimental data for Form IV 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black) and TGA. 
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1.4 Experimental data for Cocrystal 1 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black) and TGA. 
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1.5 Experimental data for Cocrystal 2 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black). 
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Appendix B 
 
2. Crystallographic data and Experimental data of the new crystal forms of 
Hesperetin 
                           
 
    
  
Cocrystal 3 
 
Cocrystal 4 
(Form I) 
 
Cocrystal 4 
(Form II) 
 
Formula 
 
C22H20N2O7
 
C21H16N2O8
 
C21H16N2O8
 
m.p. (°C) 
 
172-176 
 
198-204 
 
256-260 
 
Mol. Wt. 
 
424.40 
 
424.36 
 
424.36 
Crystal 
System 
 
Monoclinic 
 
Orthorhombic
 
Triclinic 
Space 
Group 
 
P21/c 
 
P212121
 
P-1 
 
a (Å) 
 
25.653(10)  
 
6.411(3)  
 
6.7055(15)  
 
b (Å) 
 
5.129(2)  
 
12.340(6)  
 
11.494(3)  
 
c (Å) 
 
14.880(6)  
 
23.418(3)  
 
12.402(3)  
 
α (°) 
 
90o
 
90o
 
89.635(4)o
 
β (°) 
 
103.384(7)o
 
90)o
 
85.483(4)o
 
γ (°) 
 
90o
 
90o
 
86.623(4)o
Volume 
(Å3) 
 
1904.7(13)  
 
1852.6(15)  
 
951.3(4)  
calc density 
(mg/cm3) 
 
1.480 
 
1.525 
 
1.485 
 
Solvent 
 
Methanol 
 
Methanol 
 
Methanol 
 
                         
                         
 
 
2.1 Experimental data of Cocrystal 3 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
(red) and calculated from the single crystal structure (black). 
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 .2 Experimental data of Cocrystal 4 (Form I and Form II) 
 
DSC thermogram, FT-IR spectrum and X-ray powder diffraction patterns of bulk sample 
                   
                    
2
(red), calculated from the single crystal of Form I (black) and calculated from the single 
crystal of Form II (Green). 
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